Ultragenyx Pharmaceutical Inc. today announced that the Phase 3 Aspire study evaluating GTX-102 (apazunersen) as a treatment for Angelman Syndrome is fully enrolled, with approximately 129 participants ages four to 17 with a genetically confirmed diagnosis of full maternal UBE3A gene deletion.\n\n“The accelerated enrollment of the Phase 3 Aspire study underscores the urgent need and strong desire for an effective treatment for these patients. Support from the Angelman syndrome community was critical to the achievement of this important milestone for GTX-102 with completion of enrollment in seven months. We are grateful to the study site teams, investigators, and families for their dedication and support,” said Eric Crombez, M.D., chief medical officer at Ultragenyx. “The continued developmental gains observed in the Phase 1/2 study provide a strong foundation as we advance this program with the potential to address the underlying genetic cause of this disease and enhance the quality of life for children living with Angelman syndrome.”\n\nJean-Baptiste Le Pichon, MD, PhD, FAAP, Interim Division Director, Neurology; Madison Lauren Sargent Endowed Professorship in Neurology/Angelman Syndrome, Children’s Mercy and an investigator on the Aspire study, added: “Today there are thousands of children and adults in the U.S. living with Angelman syndrome, with no cure or hope. To have a treatment in development with the potential to correct the underlying genetic error that forms the basis of Angelman syndrome, restore protein function, and recover function for patients is extremely meaningful. Completing enrollment of this study is a major milestone, and I eagerly look forward to additional data that builds on the promising preliminary results from the previous Phase 1/2 study.”\n\nEnrollment in the global Phase 3 Aspire study (NCT06617429) began in December 2024. Participants are randomized 1:1 to receive GTX-102 by intrathecal injection via lumbar puncture or to the sham comparator group for a period of 48 weeks. Participants in the active treatment group will receive three monthly 8 mg loading doses of GTX-102, followed by dosing in a maintenance period that will increase to a maximum dose of 14 mg of GTX-102 quarterly. Participants in the sham comparator group will be eligible to cross over onto treatment after completing their Week 48 assessments. The primary endpoint will be improvement in cognition assessed by Bayley-4 cognitive raw score, and the key secondary endpoint (with a 10% allocation of alpha) will be the Multi-domain Responder Index (MDRI) across the five domains of cognition, receptive communication, behavior, gross motor function, and sleep. Study completion is expected in the second half of 2026 and Ultragenyx plans to move with urgency to provide topline data and progress to regulatory submission.\n\nAbout GTX-102 (apazunersen)GTX-102 (apazunersen) is an investigational antisense oligonucleotide (ASO) therapy delivered via intrathecal administration and designed to target and inhibit expression of the UBE3A-AS to prevent silencing of the paternally inherited allele of the UBE3A gene and reactivate expression of the deficient protein. GTX-102 has been granted Breakthrough Therapy Designation, Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation from the FDA and Orphan Designation and PRIME designation from the EMA.\n\nAbout Angelman SyndromeAngelman syndrome is a rare, neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene. The maternal-specific inheritance pattern of Angelman syndrome is due to genomic imprinting of UBE3A in neurons of the central nervous system (CNS), a naturally occurring phenomenon in which the maternal UBE3A allele is expressed and the paternal UBE3A is not. Silencing of the paternal UBE3A allele is regulated by the UBE3A-AS, the intended target of GTX-102. In almost all cases of Angelman syndrome, the maternal UBE3A allele is either missing or mutated, resulting in limited to no protein expression. This condition is generally not inherited but instead occurs spontaneously. It is estimated to affect approximately 60,000 people in commercially accessible geographies.\n\nAngelman syndrome is a lifelong neurodevelopmental disorder that causes cognitive impairment, motor impairment, balance issues and debilitating seizures. Some individuals with Angelman syndrome are unable to walk and most do not speak. Anxiety and disturbed sleep can be serious challenges in individuals with Angelman syndrome. Although individuals with Angelman syndrome have a normal lifespan, they require continuous care and are unable to live independently. Angelman syndrome is not a degenerative disorder, but the loss of the UBE3A protein expression in neurons results in abnormal communications between neurons. Angelman syndrome is often misdiagnosed as autism or cerebral palsy. There are no currently approved therapies for Angelman syndrome; however, several symptoms of this disorder can be reversed in adult animal models of Angelman syndrome, suggesting that improvement of symptoms can potentially be achieved at any age.\n\nAbout UltragenyxUltragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.

Ultragenyx Completes Enrollment of Phase 3 Aspire Study

Ultragenyx Pharmaceutical Inc. announced the completion of enrollment for its Phase 3 Aspire study evaluating GTX-102 as a treatment for Angelman Syndrome, with 129 participants ages four to 17. The study, expected to complete in 2026, will assess cognitive and functional improvements in patients with the genetic disorder. The trial, randomized 1:1, will provide topline data for regulatory submission.